Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast Cancer

• Published in: Cancer genomics & proteomics Vol. 3; no. 2; p. 89
• Main Authors: Millour, Marie, Charbonnel, Catherine, Magrangeas, Florence, Minvielle, Stéphane, Campion, Loïc, Gouraud, Wilfried, Campone, Mario, Déporte-Féty, Régine, Bignon, Yves-Jean, Penault-Llorca, Frédérique, Jézéquel, Pascal
• Format: Journal Article
• Language: English
• Published: Greece 01.03.2006
• Subjects: Neoadjuvant fluorouracil; epirubicin and cyclophosphamide chemotherapy; gene expression profiles; breast cancer; drug resistance

In breast cancer treatment, FEC100 (fluorouracil, epirubicin and cyclophosphamide) chemotherapy delivered in a neoadjuvant setting is still applied empirically to all patients. The aim of this study was to establish a multigene classifier of sensitivity to neoadjuvant FEC100. cDNA nylon microarrays,...